Increased circulating miR-625-3p: A potential biomarker for patients with malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 7, Issue 7, 2012, Pages 1184-1191

  Kirschner, Michaela B ^a   Cheng, Yuen Yee ^a   Badrian, Bahareh ^b   Kao, Steven C ^a,c   Creaney, Jenette ^d,e   Edelman, J James B ^f   Armstrong, Nicola J ^g   Vallely, Michael P ^f   Musk, Arthur W ^b,d,e   Robinson, Bruce W S ^d,e   McCaughan, Brian C ^f   Klebe, Sonja ^h   Mutsaers, Steven E ^b   Van Zandwijk, Nico ^a   Reid, Glen ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Biomarker; Diagnosis; Mesothelioma; MicroRNA; Plasma

Indexed keywords

MICRORNA 29A; MIR 625 3P; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PLASMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA ISOLATION; SERUM; UPREGULATION;

EID: 84862837289     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182572e83     Document Type: Article

References (41)

1. Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009;100:1175-1183.
2. Ramazzini C. Call for an international ban on asbestos. J Occup Environ Med 1999;41:830-832.
3. Hasegawa S Tanaka F. Malignant mesothelioma: current status and perspective in Japan and the world. Gen Thorac Cardiovasc Surg 2008;56:317-323. (Pubitemid 351952058)
4. Stahel RA, Weder W, Lievens Y, Felip E; ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v126-v128.
5. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008;3:851-857.
6. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832-837.
7. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothe-lioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-1573. (Pubitemid 41434635)
8. Robinson B W, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616. (Pubitemid 37443528)
9. Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
10. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838. (Pubitemid 40839735)
11. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
12. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-10518.
13. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-675. (Pubitemid 351667616)
14. Resnick KE, Alder H, Hagan J P, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55-59.
15. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-126.
16. Ng EK, Chong W W, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorec-tal cancer screening. Gut 2009;58:1375-1381.
17. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011;80:193-208.
18. Kirschner MB, Kao SC, Edelman JJ, et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE 2011;6:e24145.
19. Kao SC, Lee K, Armstrong NJ, et al. Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology 2011;43:128-132.
20. Livak KJ Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
21. Hunter M P, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008;3:e3694.
22. Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS ONE 2009;4:e5532.
23. Balatti V, Maniero S, Ferracin M, et al. MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol 2011;6: 844-851.
24. Benjamin H, Lebanony D, Rosenwald S, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural meso-thelioma. J Mol Diagn 2010;12:771-779.
25. Busacca S, Germano S, De Cecco L, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010;42:312-319.
26. Gee G V, Koestler DC, Christensen BC, et al. Downregulated microR-NAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer 2010;127:2859-2869.
27. Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothe-lioma-A miRNA microarray analysis. Genes Chromosomes Cancer 2009;48:615-623.
28. Ivanov S V, Goparaju CM, Lopez P, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 2010;285:22809-22817.
29. Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010;70: 1916-1924.
30. Santarelli L, Strafella E, Staffolani S, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesotheli-oma. PLoS ONE 2011;6:e18232.
31. LaDou J, Castleman B, Frank A, et al. The case for a global ban on asbestos. Environ Health Perspect 2010;118:897-901.
32. Olsen NJ, Franklin PJ, Reid A, et al. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 2011;195:271-274.
33. Ohyashiki K, Umezu T, Yoshizawa S, et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS ONE 2011;6:e16408.
34. Shigoka M, Tsuchida A, Matsudo T, et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 2010;60:351-357.
35. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010;107:677-684.
36. Vasilescu C, Rossi S, Shimizu M, et al. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS ONE 2009;4:e7405.
37. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810-817.
38. Diamandis E P. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010;102:1462-1467.
39. Kulasingam V Diamandis E P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008;5:588-599.
40. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547-5551.
41. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007;129:1401-1414. (Pubitemid 46970709)